AZN vs INVA

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Innoviva exhibits a stark divergence between operational health trends and valuation; while the Piotroski F-Score of 3/9 indicates weak financial health trends, the company is fundamentally undervalued with a current price of $23.76 sitting well below both the Graham Number ($34.16) and the Intrinsic Value ($97.35). The company boasts exceptional profitability with a 65.92% profit margin and a PEG ratio of 0.35, suggesting massive growth potential relative to its current multiple. Despite a heavily bearish technical trend (10/100), the extreme liquidity (Current Ratio 14.64) and low debt/equity (0.28) mitigate immediate solvency risks. The bullish thesis is driven by deep value and explosive earnings growth, though the low F-Score warrants caution regarding operational efficiency.